Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma

Investigators will compare the novel to the standard DSC-PWI methods in twenty five GBM
patients to determine whether novel method improves image quality in tumor regions. We will
also compare accuracy of pseudoprogression (PsP) vs. early progressive disease (ePD)
determinations by the two techniques. If successful, the project will culminate in a novel
imaging method sequence optimized to monitor progression and guide treatment decisions in
post-operative GBM patients.

Inclusion Criteria:

- Histology: Glioblastoma (grade 4 astrocytoma)

- Standard-of-care, post-gd T1w image changes suggestive or consistent with of
progression.

- Standard-of-care MRI included conventional DSC-PWI without unexpected technical
difficulties.

- Methylation status of tumor available in medical record.

- Able to provide written informed consent.

Exclusion Criteria:

- Contraindications either to 3T MRI (e.g. certain metallic and electronic implants,
claustrophobia) or IV gadolinium contrast (allergy, pregnancy, breast-feeding, renal
insufficiency). Screening for these contraindications will be based on history only
(as it is for all routine outpatient clinical MRI at UWHC).

- Significant physical or mental disease which would preclude successful compliance and
participation in the study or, in the opinion of the principal investigator, or
co-investigator, constitute a hazard, such that enrollment in the study would not be
in the patient's best interest.

- Special subjects such as minors, mentally disabled persons, or prisoners.